Publications 2018

Publications auxquelles l’Aretasc a participé en 2018 :

Role of deficient DNA Mismatch repair status in patients traited with stage III colon cancer treated with Folfox adjuvant chemotherapy.

A pooled analysis from 2 randomized clinical trials. Aziz Z. ; Qian S ; Taieb J et al. Jama oncol. 2018 ; 4(3) :379-383.

Etude Ago-Ovar 2.21

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs carboplatin /pegyloted liposomal doxorubicin
/bevacizumab in patients whit platinun-sensitive recurrent ovarian cancer. Esmo 2018

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and
then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Eur J Cancer. 2018 Sep 26;103:184-194.doi:10.1016/j.ejca.2018.06.025.
[Epub ahead of print Campone M &al.

A French observational study of Nivolumab-treated lung cancer patients
in a real – world setting

Initial results on 1394 avanced non small cell
lung cancer patients. Evidens trial.
Abst. 1469P ; Esmo , 20 octob.2018.

PHARE : study randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

Swog S1007 : adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 15 décembre 2018 en session plénière au San Antonio Breast Cancer Symposium (SABCS)